HAYWARD, Calif., May 26, 2021 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced an upcoming podium
presentation on DSUVIA (sufentanil sublingual tablet 30 mcg) which
was selected for the Best Papers of the Regional Societies
session at the California Society of Plastic Surgeons
71st Annual Meeting in Monterey CA.
Hisham Seify, MD, PhD, FACS will
present data on the efficacy and safety of DSUVIA for use in
general anesthesia plastic surgery cases, and "awake" cosmetic
procedures performed at the Newport Plastic and Reconstructive
Surgery's center. The data is from an investigator-initiated trial
supported by AcelRx. Dr. Seify is a board-certified plastic
surgeon and the past-president of the Orange County Society of
Plastic Surgeons.
Session Title: Best Papers of the Regional Societies
Presentation Title: The Use of Sublingual Sufentanil for
Peri-operative Pain Management in an Outpatient and Clinic
Setting
Session Date: Monday, May 31,
2021
Session Time: 8:30 am –
10:00 am
About DSUVIA (sufentanil sublingual tablet), 30
mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in
certified medically supervised healthcare settings, such as
hospitals, surgical centers, and emergency departments, for the
management of acute pain severe enough to require an opioid
analgesic, and for which alternative treatments are inadequate.
DSUVIA was designed to provide rapid analgesia via a non-invasive
route and to eliminate dosing errors associated with intravenous
(IV) administration. DSUVIA is a single-strength solid dosage form
administered sublingually via a single-dose applicator (SDA) by
healthcare professionals. Sufentanil is an opioid analgesic
previously only marketed for IV and epidural anesthesia and
analgesia. The sufentanil pharmacokinetic profile
when delivered sublingually avoids the high peak plasma levels and
short duration of action observed with IV administration. The
European Commission approved DZUVEO for marketing in Europe and the Company is currently in
discussions with potential European marketing partners.
This release is intended for investors only. For more
information, including important safety information and black box
warning for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA®
(sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in
Europe, indicated for the
management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and one product candidate, Zalviso®
(sufentanil sublingual tablet system, SST system, 15 mcg), an
investigational product in the U.S., is being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings. DZUVEO and Zalviso are both approved products in
Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/presentation-on-the-use-of-dsuvia-for-plastic-surgery-procedures-selected-for-best-papers-session-at-the-california-society-of-plastic-surgeons-annual-meeting-301299232.html
SOURCE AcelRx Pharmaceuticals, Inc.